Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Binging brains give themselves away

Nov. 26, 2019

Diabetes drug eases nicotine withdrawal

Nov. 14, 2019

New phase II trial studies suvorexant for comorbid sleep disorder and alcohol dependence

Oct. 24, 2019

Dosing begins in NIH-funded phase II proof-of-concept study of ANS-6637

Oct. 18, 2019

AstraZeneca initiates first-in-human study of AZD-4041 in healthy volunteers

Oct. 15, 2019

Humanetics' development of radioprotectant BIO-301 supported by DoD cooperative research agreement

Oct. 2, 2019

NIDA grant supports Kinoxis' development of KNX-100 for opioid withdrawal

Oct. 1, 2019

Emergent BioSolutions, Indivior win NIH grants to study drugs for opioid use disorder

Sep. 30, 2019

NIDA award to support Ensysce's development of opioid use disorder product

Sep. 27, 2019

Omeros presents promising phase I results for PDE7 inhibitor OMS-182399 for addiction

Sep. 18, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...